Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have chosen to take part voluntarily and have signed a consent form
• Adults aged 18 to 75, of any gender
• People whose general physical functioning is rated at a mild-to-moderate level (ECOG score 0–2; confirm with trial site if unsure what this means)
• People whose liver function is rated as Grade A or B on a standard medical scale called Child-Pugh
• People who have been clinically diagnosed with primary liver cancer (hepatocellular carcinoma) that is classified as Stage III under the Chinese liver cancer staging system
• People who have not previously received first-line drug treatments such as Sorafenib for this condition
• People who have at least one tumour that can be measured on a CT or MRI scan, and that has not already been treated with radiation, freezing, or other local procedures
• People whose doctors estimate they have a life expectancy of at least 12 weeks
• People whose blood counts and organ function results meet specific minimum levels, including white blood cell count, platelet count, haemoglobin, kidney function, and liver enzyme levels (confirm exact values with trial site)
• Women of childbearing age who agree to use contraception during the trial and for six months after it ends, and who have a negative pregnancy test within 7 days before joining and are not breastfeeding
• Male participants who agree to use contraception during the trial and for six months after it ends
• People who are willing and able to attend follow-up appointments as required
• People with hepatitis B or C who are already receiving antiviral treatment that does not include interferon

Who may not be able to join:

• People who have previously received immunotherapy drugs or interferon treatment
• People who have had a severe allergic reaction to a monoclonal antibody medicine in the past
• People who are currently pregnant
• People with an immune system condition that is present from birth or has developed over time
• People with abnormal blood clotting results, a tendency to bleed, or who are currently receiving clot-dissolving or blood-thinning therapy (low-dose aspirin and low-molecular-weight heparin used as a precaution may be acceptable — confirm with trial site)
• People who currently have or have had another type of cancer at the same time, with the exception of certain fully treated skin or cervical conditions
• People who have an active infection or an unexplained fever within the past 7 days that meets a specific severity level
• People with heart conditions or heart-related symptoms that are not well managed
• People whom the investigator believes have other factors that could affect the trial results or their safety, such as alcohol or drug dependency, serious mental or physical illness, significant abnormal lab results, or difficult personal or social circumstances

Important: Always verify eligibility with the trial site directly before applying.